Neurosense Therapeutics Ltd. (NRSN) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
NeuroSense Therapeutics Ltd. is advancing its lead drug candidate, PrimeC, for ALS treatment with an upcoming FDA meeting to finalize its Phase 3 trial design and a planned submission to Health Canada by Q2 2025. The company highlights PrimeC’s promising trial results, showing significant reduction in ALS progression and improved survival rates, suggesting a strong potential market in Canada. This strategic move positions NeuroSense as a key player in addressing the urgent unmet needs of ALS patients.
For further insights into NRSN stock, check out TipRanks’ Stock Analysis page.
